graves'%20disease
GRAVES' DISEASE
Graves' disease is an autoimmune disorder that results into overproduction of thyroid hormones.
Thyrotoxicosis signs and symptoms include hyperactivity, irritability, insomnia, dysphoria, sweating, heat intolerance, palpitations, weakness, fatigue, weight loss despite increased appetite, diarrhea, steatorrhea polyuria, decreased libido, tachycardia, tremor, goiter, alopecia, gynecomastia, eyelid lag or retraction and rarely periodic paralysis.
Clinical features in thyrotoxic patient that suggests Graves's disease are ophthalmopathy, thyroid dermopathy, thyroid acropachy, diffuse goiter, antibodies to thyroid peroxidase or thyroglobulin and thyroid radionuclide scan demonstrating a diffuse goiter.

Evaluation

Two Step Process
Confirmation of thyrotoxicosis
  • Measure undetectable TSH by immunoradiometric assay
  • Confirm w/ measurement of FT4
    • FT4 is high in thyrotoxicosis
    • If FT4 is normal, FT3 should be measured because FT3 is elevated at the beginning of most episodes of thyrotoxicosis
  • For patients w/ normal TSH & FT4 levels, no further testing for thyrotoxicosis is needed
Clinical features in thyrotoxic patient that suggest Graves’ disease:
  • Ophthalmopathy
  • Thyroid dermopathy
  • Thyroid acropachy
  • Diffuse goiter
  • Antibodies to thyroid peroxidase (TPO) or thyroglobulin are present in 80% of Graves’ patients
    • Easily measured & may be used if assays for TSH-receptor antibodies are not available
  • Thyroid radionuclide scan demonstrating a diffuse goiter may suggest Graves’ disease
    • May be indicated to distinguish Graves’ hyperthyroidism from thyrotoxicosis
  • Radioactive iodine uptake is indicated when the diagnosis is in question & distinguishes causes of thyrotoxicosis having elevated or normal uptake over the thyroid gland from those w/ near-absent uptake
    • Elevated in patients w/ Graves’ disease & the pattern is diffuse
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 13 Apr 2018
Impaired endothelial-dependent microvascular reactivity appears to be predictive of albuminuria progression in Asian patients with type 2 diabetes (T2D) who have normal urine albumin levels at baseline, but not in those with microalbuminuria, a prospective longitudinal cohort study suggests.
30 May 2016
Good glycaemic control and minimizing CV risk factors are the cornerstones of T2D management. Empagliflozin, a SGLT2 inhibitor, has a unique mechanism of action that not only lowers plasma glucose but also other CV risk factors. The EMPA-REG OUTCOME® trial explored the CV benefits of this drug, and a panel of eminent speakers gathered recently to present the implications of this study and empagliflozin on clinical practice.
Stephen Padilla, 13 Apr 2018
The use of dipeptidyl peptidase-4 inhibitors may heighten the risk of inflammatory bowel disease (IBD) in patients with type 2 diabetes (T2D), according to a recent study.